Prevalence Pattern of Key Polymorphisms in the Vitamin D Receptor gene among Patients of Type 2 Diabetes Mellitus in Northeast India

Dipti Sarma, Vikram Singh Chauhan, Kandarpa Kumar Saikia, Partha Sarma, Sukanta Nath
Department of Endocrinology, Gauhati Medical College, Department of Bioengineering and Technology, GUIST, Gauhati University, Guwahati, Assam, India

Abstract

Aims: To investigate the association between Vitamin D receptor gene polymorphisms (BsmI, TaqI and FokI) and type 2 diabetes mellitus in patients in north eastern India. Settings and Design: This was a case control study with 40 cases of type 2 diabetes and 20 controls. Materials and Methods: Genomic DNA was extracted from blood and genotyped for the single nucleotide polymorphism (SNPs) of BsmI [rs1544410], TaqI [rs731236] and FokI [rs2228570] by polymerase chain reaction and gene sequencing. Genotype distribution and allelic frequencies were compared between patients and controls. Data was expressed as mean ± standard deviation. Chi square test and t test were used to compare groups. Statistical analysis was done using SAS version 9.3 software. P value of <0.05 was considered significant. Results: Body weight and BMI were significantly associated with VDR polymorphisms BsmI and TaqI while BsmI was significantly associated with HbA1C. Vitamin D deficiency was significantly greater in cases than controls. The frequency of the heterozygous genotype of the BsmI polymorphism was significantly greater in type 2 diabetics than in controls. Conclusions: Vitamin D receptor polymorphisms are associated with type 2 diabetes in our population and require larger scale studies to be considered as possible risk factors or type 2 diabetes mellitus.

Keywords: Gene polymorphisms, type 2 diabetes, Vitamin D receptor gene

INTRODUCTION

Type 2 diabetes mellitus (T2DM) is a progressive chronic disease which is marked by the inability of tissues such as liver and skeletal muscles to respond to insulin. Diabetes mellitus is well on its way to becoming a potential epidemic in India with more than 65 million diabetic individuals currently diagnosed with the disease.[1,2] It is predicted that the prevalence of diabetes will double globally from 171 million in 2000 to 366 million in 2030, with a maximum increase in India.[2] Vitamin D deficiency appears to be related to the development of T2DM and the metabolic syndrome. Recent studies have reported that high Vitamin D status provides protection against type 2 diabetes.[3,4] Vitamin D deficiency results in reduced insulin secretion in humans and rats, and its supplementation improves glucose tolerance.[5]

It is well known that Vitamin D, especially its activated metabolite 1,25-dihydroxyvitamin D3 are involved in controlling some functions of the endocrine pancreas, particularly insulin secretion; and the action of Vitamin D is mediated through binding to its nuclear receptor Vitamin D receptor (VDR).[5] The VDR primarily acts as a transcription factor. The proteins produced by the DNA that the VDR targets are responsible for various cell processes ranging from inflammation to lipid storage and calcium regulation, and deficiencies in Vitamin D are associated with many diseases, particularly type 2 diabetes.

A number of studies have been carried out in various parts of the world which have shown that polymorphisms in the VDR gene are implicated in susceptibility to T2DM. Some of the VDR polymorphisms which have been investigated for their possible associations are rs731236 (TaqI), rs1544410 (BsmI), and rs10735810 (FokI), and these were identified using the
Taql, BsmI, and FokI restriction enzymes, respectively. The results have been inconsistent and inconclusive, with wide variation in different regions and races. A study in North India explored associations between VDR polymorphisms and genetic susceptibility to type 2 diabetes and found that the genotype distribution, allele and haplotype frequencies of VDR polymorphism did not differ significantly between patients and controls.[7] However, to date, no such study exploring genetic polymorphisms in the VDR to evaluate for the risk of type 2 diabetes has been undertaken in the northeastern part of India, which was why this study was undertaken.

Materials and Methods

The present study was a case–control study carried out in a tertiary care center from August 2015 to December 2016. The study was undertaken after obtaining approval from the Institutional Ethics Committee and written informed consent was obtained from all the participants. A total of 40 patients with T2DM diagnosed as per the American Diabetes Association (ADA) (2015) criteria for diabetes were enrolled as cases. Healthy age- and sex-matched controls with no history of T2DM and normal oral glucose tolerance test as per ADA criteria of diabetes (2015) and without any family history of diabetes mellitus in first-degree relatives were enrolled as controls. Exclusion criteria for the study were people on Vitamin D supplementation within the past 3 months, patients on drugs altering Vitamin D levels (anticonvulsants, estrogen, cholestyramine, and orlistat), chronic liver disease and CKD stages 3-5.

Study design

Demographic details were taken, and clinical examination was performed for both cases and controls. Height and weight were measured and recorded to nearest 0.5 cm and 0.1 g precision, respectively, using standard measuring tape and weighing scale. Body mass index (BMI), in kg/m$^2$, was calculated. Overweight was defined as BMI 25–29.9 kg/m$^2$ and obesity was defined as BMI ≥30 kg/m$^2$ for both genders. Waist circumference was measured at the midpoint between the lower margin of the least palpable rib and the top of the iliac crest, using a stretch resistant tape providing a constant 100 g tension. Hip circumference was measured around the widest portion of the buttocks, with the tape parallel to the floor. Systolic and diastolic blood pressures (SBP and DBP) was measured as the mean of three consecutive measurements using a standard mercury sphygmomanometer from the right arm of the participant, seated for 5 min before the measurement. Hypertension was defined as SBP ≥140 mm Hg and/or DBP ≥90 mm Hg, or the use of antihypertensive drug treatment or a combination of these.

Biochemical tests

Peripheral venous blood samples were collected in the morning after an 8 h fast. All controls were screened with a standard 75 g oral glucose tolerance test to exclude the presence of diabetes mellitus. Fasting and postprandial plasma glucose was measured by the glucose oxidase enzymatic assay. Glycated hemoglobin (HbA1C), serum triglycerides, serum high-density lipoprotein cholesterol (HDLC), and serum total cholesterol (TC) was measured using an automated analyzer (VITROS® 5600 Integrated System, Ortho Clinical Diagnostics, Inc.). Low-density lipoprotein cholesterol (LDLC) was estimated from the Friedewald formula: LDL-C (mg/dL) = TC (mg/dL) - HDLC (mg/dL) - TG (mg/dL)/5. Dyslipidemia was defined as LDLC >100 mg/dL, TG >150 mg/dL, TC >200 mg/dL and/or HDLC <40 mg/dL in males or <50 mg/dL in females or with the patient on pharmacological treatment for dyslipidemia.

Serum 25-hydroxyvitamin D (25(OH)) Vitamin D was assayed by an electrochemiluminescence binding assay (Elecsys® Vitamin D total assay, Roche Diagnostics). Vitamin D deficiency was defined as per Endocrine Society guidelines[8] as a 25(OH) D below 20 ng/ml, and Vitamin D insufficiency as a 25(OH) D of 21-29 ng/ml.

Molecular analysis

Isolation of nucleic acids

DNA from fresh blood samples (of patients and healthy controls) were extracted using HiPurA™ Blood Genomic DNA Miniprep Purification Kit (Himedia Laboratories Pvt. Ltd., Mumbai, Maharashtra, India).

Qualitative polymerase chain reaction

Analysis of good quality DNA samples of cases and controls using polymerase chain reaction (PCR) sequencing for Fok1, Bsm1, and Taq1 polymorphism were performed using previously published primers.[9] After successful PCR amplification PCR products were analyzed through agarose gel electrophoresis.

Sequence analysis

50 µl of samples along with primers used for PCR were sent to a private genomics laboratory for sequencing. The interpretations of the chromatograms generated [Figure 2] were manually double-checked using bioinformatics software BioEdit. Then, these sequences were multiple aligned using software, GeneDoc and NCBI-BLAST.

Statistical analysis

For statistical analysis, data were expressed as mean ± standard deviation for normally distributed variables. Chi-square and t-test were used to compare groups as appropriate. $P <0.05$ was considered to be statistically significant. Statistical analysis was performed using SAS version 9.3 software (SAS institute, north carolina, US).

Results

Baseline characteristics of 40 patients with T2DM and 20 healthy controls are summarized in Table 1. As shown in Table 1, the mean weight of cases (62.3 kg) was significantly greater than that of controls (57.5%, $P = 0.01$). The mean BMI of cases was 24.5 kg/m$^2$ (±3.19), while in controls, it was
Table 1: Baseline parameters in the two groups

| Parameter               | Mean±SD   | P      |
|-------------------------|-----------|--------|
| Age (years)             | 49.65±9.78| 0.64   |
| Height (cm)             | 159.58±6.51| 0.57   |
| Weight (kg)             | 62.3±7.5 | 0.013  |
| BMI (kg/m²)             | 24.51±3.19| 0.0038 |
| Waist circumference (cm)| 90.05±7.35| 0.091  |
| Hip circumference (cm)  | 96.33±6.86| 0.084  |
| Waist-hip ratio         | 0.94±0.04 | 0.73   |
| Systolic BP (mmHg)      | 138.35±11.55| 0.0005 |
| Diastolic BP (mmHg)     | 89.55±6.73 | 0.003  |
| HbA1C                   | 10.09±2.24| <0.0001|
| Total cholesterol (mg/dL)| 140.68±39.06| 0.64  |
| LDL-cholesterol (mg/dL) | 75±33.46  | 0.58   |
| HDL-cholesterol (mg/dL) | 35.07±10.74| 0.03   |
| Triglycerides (mg/dL)   | 149.8±39.23| 0.0025 |
| 25 (OH) D (ng/mL)       | 13.9±8.5 | 0.0019 |

BP: Blood pressure, HbA1C: Glycated haemoglobin, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, BMI: Body mass index, 25 (OH) D: 25-hydroxyvitamin D, SD: Standard deviation

22.26 (±1.32) which was statistically significant (P = 0.0038). Other anthropometric parameters (waist circumference and waist-hip ratio) were greater in cases than controls, but the difference was not statistically significant. Both SBP and DBP were significantly greater in cases relative to controls. Among biochemical parameters, HbA1C was significantly greater in cases (P < 0.01). Among lipid profile parameters HDL-C was significantly lower in cases relative to controls (P = 0.0269). TG was significantly higher in cases than controls. TC and LDL-C were higher in cases than controls, but the difference did not achieve statistical significance. Vitamin D levels were significantly lower in cases compared to controls (13.9 ng/ml vs. 21.9 ng/ml, P = 0.0019).

Overall, Vitamin D deficiency and insufficiency were found to be present in the majority of study participants, as shown in Figure 1. Vitamin D deficiency was significantly more in cases compared to controls (85% vs. 45%, P = 0.0001). Vitamin D insufficiency was present in more controls than cases while only a minority of cases and controls were found to have sufficient levels of Vitamin D.

Analysis of the various clinical and biochemical parameters as per the three genotypes of the VDR gene [Table 2] showed that there was a significant association of the body weight and BMI with the combined mutant and heterozygous BsmI genotypes (AA + GA) compared to the wild type(GG) genotype. The body weight and BMI were also significantly correlated with the combined mutant and heterozygous TaqI genotypes (CC + TC) compared to the wild type TaqI genotype (TT). The HbA1C levels were also significantly correlated with the combined mutant and heterozygous BsmI genotypes relative to the levels in subjects harboring the wild type BsmI genotype. However, no other association was noted with any of the other clinical and biochemical parameters with BsmI polymorphisms. Analysis of the other two polymorphisms (TaqI and FokI) also failed to demonstrate any other difference between cases and controls when the wild type genotypes (TT) were compared to the mutant and heterozygous genotypes (TC + CC).

The distribution of the BsmI polymorphism [Table 3] showed that the frequency of the heterozygous GA genotype was significantly higher in cases of type 2 diabetes compared to controls (78.57% vs. 21.43%, Chi-square value: 4.037, P = 0.04), with no significant difference found in the frequency of the wild type and the mutant genotypes.

On analysis of the allelic frequencies of the BsmI polymorphism [Table 4], no significant difference was found in the mutant allele (A) between cases and controls.

On analysis of the distribution of the TaqI genotypes [Table 3], the homozygous TT genotype was the most frequent variant in cases (55%) as well as in controls (70%). The mutant CC genotype was more frequent in cases (25%) compared to controls (10%). However, there was no statistically significant difference found in any of the genotypes of TaqI between cases and controls.

On comparing allelic frequencies of the TaqI polymorphism [Table 4], there was no significant difference in the frequency of the mutant C allele between cases and controls.

On analysis of the genotypes of the FokI polymorphism [Table 3], the wild type TT variant was the most common genotype in both cases (80%) and controls (75%), with the difference not being statistically significant. The heterozygous genotype (TC) was not found in the cases analyzed. The mutant CC genotype was more frequent in cases (20%) compared to controls (10%) but the difference was not statistically significant.

Comparing the allelic frequencies of the T and C alleles of the FokI polymorphism [Table 4], no significant difference was found between the mutant C allele between cases and controls.

Figure 1: Serum 25-hydroxyvitamin D levels in cases and controls; P < 0.05 was considered significant

The distribution of the BsmI polymorphism [Table 3] showed that the frequency of the heterozygous GA genotype was significantly higher in cases of type 2 diabetes compared to controls (78.57% vs. 21.43%, Chi-square value: 4.037, P = 0.04), with no significant difference found in the frequency of the wild type and the mutant genotypes.

On analysis of the allelic frequencies of the BsmI polymorphism [Table 4], no significant difference was found in the mutant allele (A) between cases and controls.

On analysis of the distribution of the TaqI genotypes [Table 3], the homozygous TT genotype was the most frequent variant in cases (55%) as well as in controls (70%). The mutant CC genotype was more frequent in cases (25%) compared to controls (10%). However, there was no statistically significant difference found in any of the genotypes of TaqI between cases and controls.

On comparing allelic frequencies of the TaqI polymorphism [Table 4], there was no significant difference in the frequency of the mutant C allele between cases and controls.

On analysis of the genotypes of the FokI polymorphism [Table 3], the wild type TT variant was the most common genotype in both cases (80%) and controls (75%), with the difference not being statistically significant. The heterozygous genotype (TC) was not found in the cases analyzed. The mutant CC genotype was more frequent in cases (20%) compared to controls (10%) but the difference was not statistically significant.
Table 2: Anthropometric and metabolic parameters according to genotypes of vitamin D receptor polymorphisms in type 2 diabetes mellitus cases

**VDR rs1544410 (BsmI)**

| Parameter          | GG (wild) | GA + AA (heterozygous + homozygous mutant) | P  |
|--------------------|-----------|------------------------------------------|----|
|                    | Mean      | Mean                                     |    |
| Age                | 50.17±10.54 | 49.43±9.63                                | 0.83 |
| Height             | 157.17±4.95 | 160.61±6.89                               | 0.13 |
| Weight             | 55.92±9.99  | 59.64±6.61                                | 0.17 |
| BMI                | 22.62±3.26  | 23.31±2.33                                | 0.45 |
| Waist              | 89.33±7.56  | 90.36±7.37                                | 0.69 |
| Hip                | 96.5±7.59   | 96.25±6.68                                | 0.92 |
| WHR                | 0.93±0.03   | 0.94±0.04                                 | 0.36 |
| Systolic BP        | 140±10.41   | 137.64±12.11                              | 0.56 |
| Diastolic BP       | 91.83±7.004 | 88.57±6.48                                | 0.16 |
| HbA1C              | 9.22±2.09   | 10.46±2.23                                | 0.11 |
| TC                 | 157.83±40.99| 139.04±50.28                              | 0.26 |
| LDL-C              | 83.92±33.31 | 71.18±33.38                               | 0.28 |
| HDL-C              | 39.67±10.81 | 41.79±29.66                               | 0.81 |
| TG                 | 126.67±45.09| 134.21±61.2                               | 0.7  |
| Vitamin D          | 13.03±5.38  | 14.29±9.59                                | 0.67 |

**VDR rs731236 (TaqI)**

| Parameter          | TT (Wild) | TC + CC (heterozygous + homozygous mutant) | P  |
|--------------------|-----------|------------------------------------------|----|
|                    | Mean      | Mean                                     |    |
| Age                | 48.73±8.04 | 50.78±11.72                              | 0.52 |
| Height             | 159.82±6.17| 159.28±7.07                              | 0.8  |
| Weight             | 58.64±9.01 | 58.39±6.37                               | 0.92 |
| BMI                | 23.16±2.94 | 23.04±2.25                               | 0.89 |
| Waist              | 90.32±7.19 | 89.72±7.73                               | 0.8  |
| Hip                | 97.59±6.64 | 94.78±7.00                               | 0.2  |
| WHR                | 0.93±0.03  | 0.95±0.05                                | 0.09 |
| Systolic BP        | 139.45±10.44| 137.00±12.95                             | 0.51 |
| Diastolic BP       | 89.73±7.05 | 89.33±6.51                               | 0.86 |
| HbA1C              | 9.75±2.11  | 10.49±2.38                               | 0.31 |
| TC                 | 142.41±43.18| 147.44±54.39                             | 0.75 |
| LDL-C              | 73.95±32.51| 76.28±35.48                              | 0.83 |
| HDL-C              | 38.45±14.37| 44.44±34.63                              | 0.46 |
| TG                 | 126.00±55.29| 139.22±58.43                             | 0.47 |
| Vitamin D          | 13.33±8.65 | 14.62±8.50                               | 0.64 |

**VDR rs10735810 (FokI)**

| Parameter          | TT (Wild) | TC + CC (heterozygous + homozygous mutant) | P  |
|--------------------|-----------|------------------------------------------|----|
|                    | Mean      | Mean                                     |    |
| Age                | 49.91±10.22| 48.63±8.28                               | 0.75 |
| Height             | 159.31±6.64| 160.63±6.25                              | 0.62 |
| Weight             | 58.78±8.11 | 57.50±7.03                               | 0.68 |
| BMI                | 23.31±2.70 | 22.28±2.22                               | 0.32 |
| Waist              | 90.19±7.52 | 89.50±7.05                               | 0.82 |
| Hip                | 96.97±6.77 | 93.75±7.09                               | 0.24 |
| WHR                | 0.93±0.04  | 0.96±0.05                                | 0.11 |
| Systolic BP        | 138.19±10.40| 139.00±16.21                            | 0.86 |
| Diastolic BP       | 89.75±6.64 | 88.75±7.48                               | 0.71 |
| HbA1C              | 9.76±2.03  | 11.39±2.68                               | 0.06 |
| TC                 | 150.63±46.75| 120.88±48.21                             | 0.12 |
| LDL-C              | 77.47±31.57| 65.13±41.02                              | 0.36 |

Continued...
Table 2: Contd...

| Parameter | GG (wild) Mean | GA + AA (heterozygous + homozygous mutant) P Mean |
|-----------|----------------|--------------------------------------------------|
| HDL-C     | 43.28±27.71     | 32.63±8.78                                       | 0.29 |
| TG        | 136.09±57.57    | 115.38±51.37                                     | 0.36 |
| Vitamin D | 14.16±9.07      | 12.89±6.00                                       | 0.71 |

TC: Total cholesterol, TG: Triglycerides, VDR: Vitamin D receptor gene, HbA1C: Glycated haemoglobin, LDL: Low-density lipoprotein, HDL: High-density lipoprotein, BMI: Body mass index, WH: Waist-hip ratio, BP: Blood pressure

Table 3: Distribution of BsmI, TaqI and FokI polymorphisms in type 2 diabetes mellitus cases and controls

| Genotype | Cases (%) | Controls (%) | χ² | P  |
|----------|-----------|--------------|-----|----|
| BsmI     |           |              |     |    |
| GG (wild)| 12 (30)   | 10 (50)      | 2.296 | 0.129 |
| GA (heterozygous) | 23 (57.5) | 6 (30)      | 4.037 | 0.044 |
| AA (mutant) | 5 (12.5) | 4 (20) | 0.588 | 0.443 |
| TaqI     |           |              |     |    |
| TT (wild) | 22 (55) | 14 (70)      | 1.25 | 0.263 |
| TC (heterozygote) | 10 (25) | 4 (20) | 0.186 | 0.666 |
| CC (mutant) | 8 (20) | 2 (10) | 0.96 | 0.327 |
| FokI     |           |              |     |    |
| TT (wild) | 32 (80) | 15 (75)      | 0.196 | 0.657 |
| TC (heterozygote) | 0 | 3 (15) |       |     |
| CC (mutant) | 8 (20) | 2 (10) | 0.96 | 0.327 |

Table 4: Comparison of allelic frequencies of BsmI, TaqI and FokI in type 2 diabetes mellitus cases and controls

| Alleles | Cases (%) | Controls (%) | χ²  | P  |
|---------|-----------|--------------|-----|----|
| BsmI    |           |              |     |    |
| G       | 47 (58.75)| 26 (65)      | 0.6250 | 0.4292 |
| A       | 33 (41.25)| 14 (35)      |       |     |
| TaqI    |           |              |     |    |
| T       | 54 (67.5) | 32 (80)      | 2.052 | 0.1520 |
| C       | 26 (32.5) | 8 (20)       |       |     |
| FokI    |           |              |     |    |
| T       | 64 (80)   | 33 (82.5)    | 0.1076 | 0.7429 |
| C       | 16 (20)   | 7 (17.5)     |       |     |

DISCUSSION

This study was carried out to evaluate the association between VDR gene polymorphisms and T2DM in patients in North Eastern India. Previous studies in various ethnic groups have yielded inconsistent results.

Vitamin D levels were significantly lower in cases compared to controls in our study (P = 0.0019). Our study showed that Vitamin D deficiency was significantly greater in cases compared to controls. Similar to our study, Errouagui et al.[10] also demonstrated significantly higher levels of Vitamin D deficiency in patients with type 2 diabetes relative to controls. Their findings were similar to the results obtained from a study carried out in the French West Indies where the prevalence among the study subjects (all of whom were patients of T2DM) was 42%.[11] The study by Errouagui et al., which also looked at Vitamin D deficiency in healthy controls found the prevalence of Vitamin D deficiency in that group to be half that of cases (20%).[10] In our study, the prevalence of Vitamin D deficiency was much higher in both cases and controls (85% and 45%, respectively), which appears to be a reflection of the general status of Vitamin D levels in our country.[12]

The study also showed that like in the study by Errouagui et al.[10] in Moroccan subjects, Indian type 2 diabetics also had a substantially higher prevalence of Vitamin D deficiency than healthy controls. Vitamin D has been shown to play an important role in the pathogenesis of type 2 diabetes. Several preclinical studies have demonstrated that Vitamin D plays a key regulatory role in insulin secretion, beta-cell survival, and calcium flux within beta cells. A number of studies done in rats have shown that Vitamin D deficiency impairs glucose-mediated insulin secretion in rat pancreatic beta cells.[13-17] Thus, the evidence available suggests that the high Vitamin D deficient status in type 2 diabetics could be related etiologically to the disease process.

With regard to the clinical parameters assessed, we found that the body weight and BMI were significantly more in subjects with the genotypes with the presence of the mutant allele (i.e., the combined heterozygous and mutant homozygous genotypes) of the BsmI and TaqI polymorphisms. There was no difference in the other clinical parameters, between the wild type genotypes compared to the heterozygous and mutant genotypes of the three polymorphisms which were assessed (BsmI, TaqI, and FokI). Ye et al. in 2001, reported that the TT homozygosity for the TaqI SNP and the bb homozygous state for BsmI polymorphism were associated with higher obesity rates and higher BMI values in French subjects.[18] Filus et al.,[19] found an association with the BsmI polymorphism and higher BMI values, similar to our study; however, in their study, the higher BMI values were associated with the BB allele, as opposed to our study where it was the genotypes with the mutant alleles which had the higher BMI values. In their study, Bid et al. found a significant association between age and waist-hip ratio with TaqI polymorphism.[7]
We found that there was a significantly higher HbA1C level in cases carrying the mutant BsmI allele (AA + AG genotypes) compared to the wild type (GG genotype). Also, similar to our study, Al-Daghri et al.\cite{20} showed that BsmI polymorphisms were associated with an increased risk of obesity in their study carried out in the Saudi Arabian population; however, they found lower HDL cholesterol levels also in relation to BsmI polymorphisms, which was not found in our study. On the other hand, Errouagui et al.\cite{10} found that the Fok1 FF variant was significantly associated with increased levels of TC, LDL cholesterol, HDL cholesterol, and triglyceride levels in a study in Moroccan patients.

Regarding the association of T2DM and VDR polymorphisms, we found a significant difference in prevalence of the heterozygous GA genotype of the BsmI polymorphism between cases and controls. The frequency of the heterozygous GA genotype was significantly higher in cases compared to the controls. However, in case of the TaqI and FokI polymorphisms, no significant difference was found between cases and controls with respect to any of the genotypes. Similarly, Ortlepp et al.\cite{21} also found that the BsmI polymorphism was significantly associated with the risk of T2DM in the German population. Errouagui et al.\cite{10} showed that there was a strong association between Fok1 polymorphisms with type 2 diabetes in Moroccans.

On the other hand, Malecki et al.\cite{22} found no association of Fok1, ApaI, BsmI, and TaqI polymorphisms with T2DM in Poland. Ye et al.\cite{18} looked for Bsm1, TruI, Apa1 and Taq1 polymorphisms in French subjects and found no association with T2DM. Bid et al.\cite{7} found that genotype distribution, allele and haplotype frequencies of Bsm1, Fok1, and Taq1 polymorphisms did not differ significantly between patients and controls. More recently, a Tunisian study\cite{23} looked for the association of T2DM with the FokI polymorphism only and concluded that the FokI polymorphism was not associated with T2DM. Thus, with regard to the question of VDR polymorphisms and the association with T2DM, our study threw up its own results with respect to the BsmI polymorphism, concordant with the finding of some studies while differing with others, as results have varied depending on the ethnicities of the populations where these studies have been carried out. The study was limited by the small sample size. Furthermore, the Apa1 polymorphism was not looked for in our study. While small sample sizes have been a common limitation of every study carried out in this area, the number of polymorphisms looked for has also varied from study to study. The study findings are significant as this is the first study of its kind to have been carried out in the northeastern region of India. To validate the findings of our study, however, a large-scale study design is required.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Joshi SR, Parikh RM. India – Diabetes capital of the world: Now heading towards hypertension. J Assoc Physicians India 2007;55:323-4.
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
3. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 2007;92:2017-29.
4. Knekt P, Laaksonen M, Mattila C, Härkänen T, Marniemi J, Heliovaa M, et al. Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 2008;19:666-71.
5. Kumar S, Davies M, Zakaria Y , Mawer EB, Gordon C, Olukoga AO, et al. Improvement in glucose tolerance and beta-cell function in a patient with vitamin D deficiency during treatment with vitamin D. Postgrad Med J 1994;70:440-3.
Sarma, et al.: VDR polymorphisms in T2DM

6. Calle C, Maestro B, García-Arencibia M. Genomic actions of 1,25-dihydroxyvitamin D3 on insulin receptor gene expression, insulin receptor number and insulin activity in the kidney, liver and adipose tissue of streptozotocin-induced diabetic rats. BMC Mol Biol 2008;9:65.

7. Bid HK, Konwar R, Aggarwal CG, Gautam S, Saxena M, Nayak VL, et al. Vitamin D receptor (FokI, BsmI and TaqI) gene polymorphisms and type 2 diabetes mellitus: A North Indian study. Indian J Med Sci 2009;63:187-94.

8. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1911-30.

9. Wang Y, Cui ZQ, Luo TB, Liu L. Correlations of VDR and VDBP genetic polymorphisms with susceptibility to adolescent idiopathic scoliosis and efficacy of brace treatment. Genomics 2016;108:194-200.

10. Errouagui A, Benrahma H, Charoute H, Ghalim N, Barakat A, Kandil M, et al. Relationship between vitamin d receptor (VDR) gene polymorphisms and susceptibility to Type 2 diabetes mellitus in Moroccans population. Int J Innovation Appl Stud 2014;8:1. Available from: http://www.ijias.issr-journals.org/abstract.php?article=IJIAS-14-214-01. [Last accessed on 2017 May 29].

11. Vélayoudom-Céphise FL, Larifla L, Donnet JP, Maimaitiming S, Deloumeaux J, Blanchet A, et al. Vitamin D deficiency and cardiovascular risk factors in Caribbean patients with type 2 diabetes. Diabetes Metab 2011;37:540-5.

12. Ritu G, Gupta A. Vitamin D deficiency in India: Prevalence, causalities and interventions. Nutrients 2014;6:729-75.

13. Norman AW, Frankel JB, Heldt AM, Grodsky GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980;209:823-5.

14. Chertow BS, Sivitz WI, Baranetsky NG, Clark SA, Waite A, Deluea HF, et al. Cellular mechanisms of insulin release: The effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983;113:1511-8.

15. Kadowaki S, Norman AW. Dietary vitamin D is essential for normal insulin secretion from the perfused rat pancreas. J Clin Invest 1984;73:759-66.

16. Tanaka Y, Seino Y, Ishida M, Yamaoka K, Yabuuchi H, Ishida H, et al. Effect of vitamin D3 on the pancreatic secretion of insulin and somatostatin. Acta Endocrinol (Copenh) 1984;105:528-33.

17. Cade C, Norman AW. Vitamin D3 improves impaired glucose tolerance and insulin secretion in the vitamin D-deficient rat in vivo. Endocrinology 1986;119:84-90.

18. Ye WZ, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit J, Velho G, et al. Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset. Eur J Endocrinol 2001;145:181-6.

19. Filus A, Trzmiel A, Kuliczewska-Płatkej J, Twarowska U, Jedrzejuk D, Milewicz A, et al. Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome. Aging Male 2008;11:134-9.

20. Al-Daghri NM, Al-Attas OS, Alkharfy KM, Khan N, Mohammed AK, Vinodson B, et al. Association of VDR-gene variants with factors related to the metabolic syndrome, type 2 diabetes and vitamin D deficiency. Gene 2014;542:129-33.

21. Ortlepp JR, Lauscher J, Hoffmann R, Hanrath P, Joost HG. The vitamin D receptor gene variant is associated with the prevalence of type 2 diabetes mellitus and coronary artery disease. Diabet Med 2001;18:842-5.

22. Malecki MT, Frey J, Moczulski D, Kluapa T, Kozek E, Sieradzki J, et al. Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population. Exp Clin Endocrinol Diabetes 2003;111:505-9.

23. Mahjoubi I, Kallel A, Shai MH, Ftohui B, Ben Halima M, Jemaa Z, et al. Lack of association between FokI polymorphism in vitamin D receptor gene (VDR) & type 2 diabetes mellitus in the Tunisian population. Indian J Med Res 2016;144:46-51.